02 February 2021 | Statements

Unitaid statement regarding Ivermectin as a potential COVID-19 treatment

Ivermectin, as well as other repurposed products, has been suggested as a potential treatment for COVID-19 based on preliminary promising evidence – further data is needed to support a definitive recommendation either for or against its use for COVID-19.

Unitaid has collaborated with the University of Liverpool to conduct the preliminary desk analysis of existing trials evaluating ivermectin in different countries of the world, in order to facilitate a review by WHO.

The preliminary analysis has incorporated data from randomised clinical studies that have been completed in Bangladesh, Egypt, Iran, India, Iraq, Lebanon, Pakistan, Turkey, Nigeria, Argentina, Mexico, and Spain.

In the coming weeks, results from additional trials in other countries are expected, and an in-depth analysis will be conducted by WHO to determine next steps, including the potential need for further targeted clinical studies.


Media contact: 

Hervé Verhoosel | +44 7729 618634 | verhooselh@unitaid.who.int

View All News

Featured News

30 November 2022

Unitaid highlights gender gaps and calls for innovative strategies to reach all people at risk ahead of World AIDS Day

Read More

17 November 2022

Unitaid and global health partners reach 90% treatment target for women screened with cervical cancer in multi-country pilots 

Read More

Sign Up for Unitaid Updates

  • This field is for validation purposes and should be left unchanged.